Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer
Ontology highlight
ABSTRACT: This study is a retrospective study to compare the efficacy and safety between trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) with TAS-102 monotherapy in refractory metastatic colorectal cancer (mCRC) from November 2020 to October 2022 at the Hunan Cancer Hospital.
DISEASE(S): Metastatic Colorectal Adenocarcinoma,Colorectal Neoplasms
PROVIDER: 60837 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA